ALBO | Albireo Pharma Company profile
Company profileAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo?s lead product candidate, odevixibat (A4250), is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo?s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.
Address10 Post Office Square Key Persons / Board of Directors
Videos about Albireo Pharma | NotesJump to (Finance sites)         ResearchInvestor pageir.albireopharma.comIf you are looking for News & events, Press Release, they are available on their Investors Relationssite. Their Official Profiles  Other stocks            Support this projectIf you want to help pay for server cost or for improving this tool. You can send it via Paypal. Social MediaRecommended Books Buy on Amazon While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology. |
